Imiglucerase biosimilar?

What are biosimilars and how do they compare to their reference products?

Biosimilars are biologic medicinal products that are highly similar to an existing biologic medicine, known as a reference product or originator product. Biosimilars have been shown to have no clinically meaningful differences from the reference product in terms of safety, purity, and potency.

What is Ceredase, and what is its connection to Imiglucerase biosimilars?

Ceredase is a branded biologic medicine containing the enzyme glucocerebrosidase. It is used to treat Gaucher's disease, a rare genetic disorder. Ceredase was initially developed by Genzyme, and its trademark has been owned by Sanofi since 2011. [1]

Imiglucerase is a recombinant form of the glucocerebrosidase enzyme, and it has been marketed under several brands, including Cerezyme (Sanofi) and VPRIV (Shire, previously Genzyme). Imiglucerase biosimilars, on the other hand, would be cheaper alternatives to these branded products, potentially offering savings for patients and healthcare systems.

Can biosimilars enter the U.S. market, and what is the current regulatory environment?

According to the Biologics Price Competition and Innovation Act of 2009 (BPCIA), biosimilars can be approved by the FDA after demonstrating that they meet certain requirements. [2] Biosimilars must be shown to be highly similar to a reference product in terms of quality, safety, and efficacy, and the FDA considers clinical trials and other evidence to compare these biosimilars with the reference product.

How does the patent landscape relate to Imiglucerase biosimilars?

As for patents, the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for a biosimilar of Cerezyme (Imiglucerase). The patent landscape for biosimilars can be complex, and there are ongoing litigations and challenges by some companies attempting to protect their reference products' patents. [3] It's essential to note that these legal disputes can delay market access for biosimilars.

Why are companies challenging the patent for Imiglucerase biosimilars?

The patent expiration of the originator product can give biosimilar manufacturers an opportunity to enter the market. Since the patent for Cerezyme (Imiglucerase) will expire in a certain year [4], manufacturers may be challenging its validity to potentially delay the patent expiration and market entry of biosimilars.

What happens if a biosimilar manufacturer challenges the patent successfully?

If the biosimilar manufacturer is successful in challenging the patent, it may allow for earlier market entry, as the exclusivity of the originator product is lifted. However, the patent's validity may still be questioned in court, and the FDA may consider the biosimilar before the patent expires, depending on the specific circumstances.

Sources:

[1] Ceredase (glucocerebrosidase) [Package Insert]. (n.d.). Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/018644s024lbl.pdf

[2] FDA (2019) Biosimilars: Information for Healthcare Professionals. Available at: https://www.fda.gov/drugs/biosimilars/biosimilars-information-healthcare-professionals

[3] (n.d.). Biosimilars patent challenges in 2020 and 2021. Retrieved from https://www.drugs.com/biosimilars/patent-challenges-in-2020-and-2021.html

[4] (n.d.). Cerezyme Generic - When will a Generic Version of Cerezyme be available? Retrieved from https://www.drugs.com/cerezyme-generic.html